Top Biotech Stocks To Invest In Right Now

The final week of August 2017 finished with no IPOs. The month’s five offerings raised $777 million, making it the slowest August in six years. The week was headlined by Roku’s initial filing, along with filings from four biotechs, two Chinese education companies, a surgical robotics company and a marketplace for motorcycles; three companies updated their filings, growing the active pipeline to 41 companies.

Year-to-date performance for 2017 IPOs rallied to 17%, up from 11% a week ago (and 8% as of 8/18). After turning positive last week, average aftermarket returns increased to 6%. The recent strong returns have largely been driven by biotech outperformance over the past two weeks. 66% of the 92 IPOs this year are currently trading above issue price.

This week, we released our Fall 2017 US IPO Preview, following the release of our Non-US IPO Preview last week. We also put out a pre-IPO report on Social Capital Hedosophia Holdings (Pending:IPOAU), a VC-managed SPAC planning to acquire a large private tech company.

Top Biotech Stocks To Invest In Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Brian Orelli]

    The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn’t think a few months will really matter: “We don’t really feel that’s going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we’re very well prepared to be ready to launch following approval.”

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.

Top Biotech Stocks To Invest In Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Brian Feroldi]

    Data source: Alkermes. GAAP = generally accepted accounting principles.

    What happened with Alkermes this quarter?
    Sales of Alkermes’opioid- and alcohol-abuse prevention drug Vivitrol grew 7% to $62.7 million. Sales of the company’sschizophrenia drugAristadarose 62% to $29.2 million. Manufacturing and royalty revenue related toJohnson & Johnson’s schizophrenia drugs jumped 15% to $68.8 million. Manufacturing and royalty revenue related toAcorda Therapeutics’ multiple sclerosis drugfell3% to $28.3 million. Research and development revenue earned as part of its collaboration withBiogen (NASDAQ:BIIB) for BIIB098 — which used to be called ALKS 8700 — was $17.5 million.

    Looking beyond the financials, here’s an overview of the key events from the period:

  • [By Chris Lange]

    Biogen Inc. (NASDAQ: BIIB) is expected to report its first-quarter results early on Tuesday. The consensus forecast calls for $5.92 in earnings per share (EPS) and revenue of $3.15 billion. Shares of Biogen ended last week at $263.02. The consensus analyst price target is all the way up at $371.97. The 52-week trading range is $244.28 to $370.57.

  • [By Cory Renauer]

    There’s a lot for investors to like aboutAmgen Inc. (NASDAQ:AMGN) andBiogen Inc. (NASDAQ:BIIB). Both of these biotech stocks have produced tremendous returns over the past couple of decades, and the businesses they represent still generate enormous profits.

Top Biotech Stocks To Invest In Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

  • [By Stephan Byrd]

    ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Top Biotech Stocks To Invest In Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By ]

    This week we get our first look at quarterly numbers from major drug and biotech giants such as AbbVie (ABBV)  , Amgen (AMGN)  , Biogen (BIIB) , Biomarin Pharmaceuticals (BMRN)  and Action Alerts PLUS holding Eli Lilly (LLY) , which all provide the market a glimpse of how the first quarter was for the industry over the next few days,” according to Real Money Pro columnist Bret Jensen.

  • [By Ethan Ryder]

    Wayne Hummer Investments L.L.C. trimmed its position in shares of Amgen (NASDAQ:AMGN) by 11.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,311 shares of the medical research company’s stock after selling 303 shares during the period. Wayne Hummer Investments L.L.C.’s holdings in Amgen were worth $394,000 at the end of the most recent quarter.

  • [By Cory Renauer]

    Sanofi took the assessment and started engaging end payers to see if any would offer easy reimbursement for a lower net price that reflects ICER’s assessment, and the industry listened. As of July 1, the partners will cut the net price of Praluent in return for straightforward access for around 25 million Americans covered by theExpress Scripts (NASDAQ:ESRX) national formulary. Thepharmacy benefits manager, and will also remove formulary access for its main competitor, Amgen’s (NASDAQ:AMGN) Repatha.

  • [By ]

    For example, if you buy 100 shares of theNasdaq100ETF(NYSE: QQQ), you’re theoretically buying 11.9 shares of Apple (NASDAQ: AAPL)… 7.7 shares of Facebook (NASDAQ: FB)… 1.8 shares ofAmgen(NASDAQ: AMGN)… 2.6 shares of Comcast (NASDAQ: CMCSA)… and even smaller amounts of about 95 different companies.

Leave a Reply

Your email address will not be published. Required fields are marked *